Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Conditions: Leukemia; Lymphoma Intervention: Biological: :Anti-CD22-CAR Sponsors: Kecellitics Biotech Company Ltd; Hebei Yanda Ludaopei Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials